
1. Future Microbiol. 2021 Nov;16:1341-1370. doi: 10.2217/fmb-2021-0019. Epub 2021
Nov 10.

Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV.

Aherfi S(1)(2)(3), Pradines B(2)(4)(5)(6), Devaux C(2), Honore S(7)(8), Colson
P(1)(2)(3), Scola B(1)(2)(3), Raoult D(1)(2).

Author information: 
(1)Aix-Marseille Université, Assistance Publique - Hôpitaux de Marseille (AP-HM),
Marseille, 13005, France.
(2)Institut Hospitalo-Universitaire (IHU) - Méditerranée Infection, Marseille,
13005, France.
(3)Microbes, Evolution, Phylogeny & Infection (MEΦI), Marseille, 13005, France.
(4)Unité Parasitologie et Entomologie, Département Microbiologie et Maladies
Infectieuses, Institut de Recherche Biomédicale des Armées, Marseille, 13005,
France.
(5)Aix-Marseille Univ, IRD, SSA, AP-HM, VITROME, Marseille, 13005, France.
(6)Centre national de référence du paludisme, Marseille, 13005, France.
(7)Aix Marseille Université, Laboratoire de Pharmacie Clinique, Marseille, 13005,
France.
(8)AP-HM, hôpital Timone, service pharmacie, Marseille, 13005, France.

Since the beginning of the COVID-19 pandemic, large in silico screening studies
and numerous in vitro studies have assessed the antiviral activity of various
drugs on SARS-CoV-2. In the context of health emergency, drug repurposing
represents the most relevant strategy because of the reduced time for approval by
international medicines agencies, the low cost of development and the well-known 
toxicity profile of such drugs. Herein, we aim to review drugs with in vitro
antiviral activity against SARS-CoV-2, combined with molecular docking data and
results from preliminary clinical studies. Finally, when considering all these
previous findings, as well as the possibility of oral administration, 11
molecules consisting of nelfinavir, favipiravir, azithromycin, clofoctol,
clofazimine, ivermectin, nitazoxanide, amodiaquine, heparin, chloroquine and
hydroxychloroquine, show an interesting antiviral activity that could be
exploited as possible drug candidates for COVID-19 treatment.

DOI: 10.2217/fmb-2021-0019 
PMCID: PMC8579950
PMID: 34755538  [Indexed for MEDLINE]

